Vivanza (Vardenafil) is commonly used across therapeutic domains where additional symptomatic support for functional impairment is needed, and is indicated for men with Erectile Dysfunction (ED). The medication is applied in addressing symptom clusters related to the inability to get or keep a hard penis sufficient for sexual activity.

The support is relevant in conditions characterized by periods of heightened physiological stress, such as ED linked to Diabetes Mellitus or following nerve-sparing radical prostatectomy. The medication plays a role in managing symptoms that interfere with functional sexual activity and is used in clinical settings that require short-term symptomatic assistance. This support contributes to improved day-to-day comfort by helping the patient cope with symptom fluctuations and supports engagement in sexual intimacy, thereby supporting general well-being during symptomatic phases.

Quick Fact: Symptomatic support for functional rigidity
The medication is primarily indicated for Erectile Dysfunction (ED), and it may assist with functional stability in complex cases, such as those involving Diabetes or status following prostate surgery.

Regulatory References

1. European Medicines Agency therapeutic overview

Eligibility Map: Who can and cannot use Vivanza — Official Regulatory Information

Eligibility Scope

Vardenafil is indicated for use only in adult men (18 years and over). It is not indicated for use in women, including during pregnancy or lactation, nor in any pediatric population.

Populations for whom use is Contraindicated (Must not use):

• Patients taking any form of nitrates or nitric oxide donors.
• Patients taking guanylate cyclase (GC) stimulators (e.g., riociguat).
• Patients with severe hepatic impairment (Child-Pugh C) or end-stage renal disease requiring dialysis.
• Patients with a recent history of stroke or myocardial infarction (within six months).
• Patients with a history of vision loss due to Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
• Patients with severe cardiovascular disorders where sexual activity is deemed inadvisable.

Condition-Specific Eligibility Restrictions (Use with Caution):

• Use requires caution in patients with moderate hepatic impairment (Child-Pugh B) or severe renal impairment; a lower starting dose is often recommended.
• Use requires caution in patients with anatomical deformation of the penis (e.g., Peyronie's disease) or conditions that may predispose to priapism (e.g., sickle cell anemia).
• Patients on stable alpha-blocker therapy should initiate vardenafil at the lowest recommended dose.

---

Resulting Eligibility Structure

Official eligibility statements classify patient suitability based on absolute contraindication, age exclusion, and conditional use.

• Contraindicated populations are primarily defined by concurrent medication use (Nitrates/GC Stimulators) and severe organ/cardiovascular dysfunction.
• Age-related eligibility strictly excludes individuals under 18 years, as safety and efficacy are not established in children.
• Conditional use is mandated for patients with moderate organ impairment or specific anatomical/blood disorders, requiring careful regulatory consideration.

Connection to the overall eligibility profile: The official regulatory profile strictly limits Vardenafil use to adult males who do not possess specific high-risk systemic conditions or use contraindicated concurrent medications. Eligibility is defined by clear exclusionary rules regarding severe hepatic, renal, or unstable cardiovascular status, which must be assessed prior to administration.

Interactions with other medicines and products

The interaction profile of Vivanza (Vardenafil) is defined by strict prohibitions and restrictions related to its metabolic pathway and pharmacodynamic effects, as documented in regulatory labeling.

Contraindicated Combinations

Co-administration is strictly prohibited with Nitrates and Nitric Oxide Donors due to a severe pharmacodynamic interaction resulting in an additive vasodilatory effect and risk of life-threatening hypotension. The combination with Guanylate Cyclase (GC) Stimulators (e.g., riociguat) is also contraindicated.

Pharmacokinetic and Metabolic Restrictions

Vardenafil is predominantly metabolized via the CYP3A4 enzyme. Highly potent CYP3A4 inhibitors, such as the HIV Protease Inhibitors Ritonavir and Indinavir, are contraindicated as co-administration significantly increases Vardenafil plasma exposure ( AUC and C max). Moderate CYP3A4 inhibitors, like erythromycin, also increase exposure.

Other Documented Interactions

Interaction Type	Interacting Substance/Class	Constraint/Outcome
Pharmacodynamic	Alpha-Blockers (e.g., tamsulosin)	Potential for additive blood pressure lowering effect.
Timing Rule	Nitrates (Emergency Use)	A minimum of 24 hours must elapse after the last dose of Vardenafil.
Substance Interaction	Grapefruit Juice	Expected to increase Vardenafil plasma concentrations; must be avoided.

Co-administration with Class IA or Class III Antiarrhythmics may pose an additive risk of QTc interval prolongation. Use is contraindicated in patients with severe hepatic impairment.

Vivanza is a highly selective inhibitor of the phosphodiesterase type 5 (PDE5) enzyme. This enzyme is primarily responsible for the degradation of a key second messenger, cyclic guanosine monophosphate (cGMP), in specific smooth muscle tissues. The molecular interaction of Vivanza with the active site of PDE5 causes a competitive inhibition, effectively blocking the hydrolysis of cGMP into its inactive metabolite, GMP.

This sustained molecular blockade results in a significant accumulation of cGMP within the cytoplasm of corpus cavernosum smooth muscle cells. Elevated cGMP levels activate protein kinase G (PKG), which in turn drives the phosphorylation of various downstream proteins. This precise intracellular signaling cascade facilitates vascular smooth muscle relaxation by promoting the sequestration of calcium ions. The net physiological consequence of this smooth muscle modulation is a modification of local blood flow dynamics in the target tissues. Furthermore, this sustained cGMP elevation mechanism is also associated with effects on overall endothelial function.

Vivanza is administered exclusively via the oral route as either a film-coated tablet or an orally disintegrating tablet (ODT). Usage is intermittent and taken as needed, with a maximum frequency of once per day.

The medicine must be administered approximately 25 to 60 minutes prior to anticipated sexual activity. The recommended starting dose for most adults is 10 mg, with the available dosing range spanning 5 mg to 20 mg. The maximum recommended dose is 20 mg.

Special administration conditions dictate that the drug can be taken with or without food; however, a high-fat meal may delay the onset of action. The ODT formulation must be placed on the tongue to dissolve without liquid. The 10 mg ODT form is not interchangeable with the 10 mg film-coated tablet due to differing systemic exposure.

Population-specific adjustments are required for certain groups. For older adults (ge 65 years), a lower starting dose of 5 mg may be considered. Patients with moderate hepatic impairment should not exceed a maximum dose of 10 mg. When used concurrently with alpha-blockers, treatment must begin at the lowest starting dose of 5 mg. As the medication is used on an as-needed basis, there are no instructions for a missed dose.

---

General Administration Parameters

Parameter	Instruction
Route of Administration	Oral
Maximum Frequency	Once per day (as needed)
Dosing Range	5 mg to 20 mg
ODT Handling	Dissolves on tongue, no liquid required

Research evidence / Overview of studies for Vivanza (Vardenafil)

Evidence for use in Erectile Dysfunction (Broad Scope)

The clinical evaluation of Vardenafil was primarily based on short-term, randomized controlled trials (RCTs), typically double-blind and placebo-controlled. These studies were designed to explore how the outcomes of the Vardenafil groups compared to the outcomes of the placebo groups in adult men diagnosed with Erectile Dysfunction (ED). Research examined patient-reported experiences and functional outcomes over a defined time interval, typically 12 weeks.

In these studies, researchers monitored functional outcomes using specialized questionnaires, such as the International Index of Erectile Function (IIEF). Studies reported measurements indicating that a higher proportion of successful sexual attempts were observed in the Vardenafil cohorts compared to the placebo groups. Comparative evidence directly assessing Vardenafil against all other treatments in its pharmacological category in head-to-head clinical trials remains limited.

---

Evidence for use in Specific Comorbidity Groups

Research also explored Vardenafil in the context of conditions associated with functional limitations, specifically ED linked to Diabetes Mellitus. Researchers conducted dedicated, randomized, placebo-controlled trials to examine the findings in this specific subgroup of adult men. Studies reported measurements indicating that a higher proportion of successful sexual attempts were observed in the Vardenafil groups during the study period compared to those receiving placebo.

---

Evidence in Surgical Subpopulations

Research evaluated Vardenafil in men with ED following nerve-sparing radical prostatectomy—a complex condition marked by functional limitations. The evidence base includes specific randomized, placebo-controlled trials. Studies reported measurements indicating a higher proportion of successful intercourse attempts in the Vardenafil cohorts compared to the placebo groups. The functional success rates reported for this postsurgical group reflect the complex nature of ED following surgery.

---

What Remains Uncertain or Under-Studied

Long-term follow-up data were often gathered primarily to study safety and tolerability rather than to definitively monitor the sustained maintenance or durability of functional results over multiple years. The available evidence is insufficient for some specific, less common causes of ED. Comparative research and longer-term observational data remain important areas for study.

Key Studies & References

1. Efficacy and Safety of Flexible-Dose Vardenafil in Men With Type 1 Diabetes and Erectile Dysfunction

Common questions about Vivanza (FAQ)

---

Q: Is it true that Vivanza can interact with common heart medications?

Official regulatory information indicates that Vivanza has properties that can lead to a temporary drop in blood pressure. Because of this, caution is advised when the medicine is used alongside other blood pressure-lowering agents, also known as antihypertensive drugs. Official information indicates that the combination may be associated with an additive effect on blood pressure.

Q: What is the longest time Vivanza stays active in the body?

According to the official product information, the active component, Vardenafil, has a terminal plasma elimination half-life of approximately four to five hours. The half-life represents the time required for half of the medicine's concentration to decrease in the body.

Q: Are there any reported cases of Vivanza causing allergic reactions?

Official safety information reports that allergic reactions have been documented in postmarketing settings. These rare reports have included allergic edema and angioedema, which involve swelling of the face, lips, or throat.

Q: Can men of any age use Vivanza?

The medicine is indicated solely for use in adult men who are 18 years of age and older. Official guidelines describe that adjustments to the starting dose are often considered for men aged 65 years and older.

Q: Is Vivanza the same type of medicine as Viagra or Cialis?

Vivanza contains the active substance Vardenafil, which belongs to the pharmacological class known as Phosphodiesterase type 5 (PDE5) inhibitors. This is the same drug class as Sildenafil (the active ingredient in Viagra) and Tadalafil (the active ingredient in Cialis).

Q: Is there a link between Vivanza and back pain?

Official regulatory documents list back pain as a reported adverse reaction associated with the use of the medicine.

Q: Can Vivanza be used by someone with kidney problems?

Dosage adjustments are not typically required for individuals with mild to moderate renal impairment. However, official safety information indicates that the medicine is not recommended for use in patients with end-stage renal disease who require dialysis.

Q: What are the risks if Vivanza is taken with recreational drugs?

Regulatory documents contain a specific contraindication regarding the use of Vivanza with amyl nitrite, which is sometimes used recreationally. Combining these substances is prohibited because it can lead to a severe and life-threatening drop in blood pressure.

Q: What is the purpose of the different strengths (e.g., 5mg, 10mg) of Vivanza?

The various available strengths, such as 5 mg, 10 mg, and 20 mg, are designed to support dose adjustment. These strengths support necessary dose adjustment based on individual factors, including age, tolerance, and the presence of other medical conditions or interacting medications.

Q: Is Vivanza a medicine that I will need to use indefinitely?

According to the official dosage and administration instructions, Vivanza is indicated for intermittent use. This means the medicine is taken as needed before sexual activity and is not intended for continuous or chronic daily treatment.

Q: Does alcohol reduce or change the effectiveness of Vivanza?

Official patient information indicates that alcohol can enhance the blood pressure lowering effects of Vivanza, which may increase the risk of side effects such as dizziness. Official patient information indicates that excessive alcohol intake may also be associated with temporarily interfering with the ability to get an erection.

Q: Can Vivanza be split or crushed to make it easier to swallow?

The orally disintegrating tablet (ODT) formulation should never be chewed, crushed, or split and must be allowed to dissolve entirely on the tongue. Information about splitting or crushing the film-coated tablet is not generally provided in product labels, and instructions would be available from a dispensing pharmacist.

Q: Is Vivanza considered a controlled substance?

Vivanza is classified by regulatory bodies as a prescription-only medication. However, it is not listed as a federally controlled substance.

Q: Why is Vivanza prescription-only?

The requirement for a prescription is due to serious safety considerations documented in the official labeling. Use is contraindicated in patients with specific severe cardiovascular conditions and when taken with certain other medications, like Nitrates, necessitating a mandatory medical assessment before administration.

Q: Can Vivanza affect the results of blood tests?

Official adverse reaction reports from clinical trials note that an increase in the enzyme creatine kinase has been observed. This is an enzyme level that may be measured in the blood.

Q: What is the primary way Vivanza is eliminated from the body?

Following its metabolism, the active ingredient is primarily eliminated from the body as metabolites. According to the official product information, approximately 91 to 95% of the dose is eliminated via the faeces.

Q: Is there a risk of dependency or addiction with Vivanza?

Patient information published by various health authorities explicitly states that the active component, Vardenafil, is not addictive.

Q: What is the difference in how Vivanza works compared to a generic version of the same drug?

The generic version of the drug contains the exact same active substance, Vardenafil. Therefore, it works by the identical mechanism—inhibiting the PDE5 enzyme—as the branded product.

Q: Are there any known interactions between Vivanza and common antibiotics?

Certain types of antibiotics, such as erythromycin and clarithromycin, are known to interact with Vivanza. These medicines can affect the body's ability to metabolize the drug, potentially increasing the levels of Vardenafil in the bloodstream.

Q: Does official research show Vivanza is effective for all degrees of the condition it treats?

Studies and official research have demonstrated effectiveness in men across a wide range of erectile dysfunction (ED) severity. This includes effectiveness reported in men with ED associated with diabetes mellitus and ED following prostatectomy surgery.

Official Storage and Disposal Requirements

Vivanza (Vardenafil) must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). The medicine must be kept in the container it came in, tightly closed, and stored away from direct light, excess heat, and moisture. It is explicitly stated in regulatory labeling to keep from freezing and not to use outdated medicine.

For the orally disintegrating tablets (ODT), do not remove the tablet from the blister pack until immediately before use.

Vivanza must be stored out of the sight and reach of children.

For disposal, do not flush the medicine down the toilet or throw it in the household trash. Patients are required to ask a pharmacist or healthcare professional how to dispose of unused medication according to local regulations and established take-back programs.